Polarean Expands Ascend Imaging Partnership to Accelerate US Market Growth

Polarean expands Ascend Imaging deal to 19 US states – why this matters for POLX

Polarean Imaging has widened its commercial partnership with Ascend Imaging, a US specialist sales outfit in radiology and radiation oncology. The key change: coverage jumps from four US states to 19, with Ascend continuing as a non-exclusive, independent manufacturer’s representative for Polarean’s Xenon MRI platform.

For a company focused on growing adoption of its FDA-approved XENOVIEW hyperpolarised xenon MRI, this is a meaningful footprint upgrade. It is not a revenue announcement, but it is unequivocally about sales reach and pace.

What exactly has changed in the Ascend agreement

• Ascend Imaging remains a non-exclusive representative, promoting and supporting sales of Polarean’s Xenon MRI platform.
• Geographic coverage expands to 19 US states, up from four under the original agreement.
• Ascend will identify new prospects, drive engagement, and support negotiations and closures, complementing Polarean’s in-house commercial team.

In practical terms, Polarean is leveraging an experienced channel partner with deep relationships in hospital imaging to create more top-of-funnel activity and shorten time to deal closure.

Why this is positive for US adoption of XENOVIEW

Ascend Imaging’s focus on advanced imaging and AI, and its long-standing provider relationships, makes it a natural fit for a novel lung imaging modality. The CEO, Christopher von Jako, highlights that the collaboration has already been “highly productive” and that expanding into additional states should accelerate adoption.

From an investor perspective, three positives stand out:

• Scale and speed: Expanding to 19 states broadens the hunting ground and should lift lead volume.
• Targeted access: A specialist representative can get to decision-makers in radiology and pulmonology faster, which matters for new imaging workflows.
• Reimbursement tailwind: Ascend notes that hospitals are seeking “innovative solutions that are supported by reimbursement.” That is a powerful adoption catalyst for new imaging services, even though specific reimbursement details are not disclosed.

What the RNS does not disclose

Important gaps remain, which investors should note:

• No financial terms revealed: Commission rates, cost implications, and any sales targets are not disclosed.
• No duration or state list: The exact states and contract term are not specified.
• No immediate sales impact: There is no guidance on expected revenue uplift, pipeline size, or timeline to installations.

This is a classic go-to-market update rather than a bookings announcement. The value will be proven in future RNSs showing new site wins, purchase orders, and installed base growth.

How this fits Polarean’s commercial strategy

Polarean is positioning itself as a leader in functional lung MRI, offering a non-invasive, radiation-free platform built around hyperpolarised xenon gas and XENOVIEW, the first and only FDA-approved inhaled xenon MRI contrast agent in the US. Hospitals need crisp clinical value and a viable economic case to adopt new imaging – the combination of specialist sales coverage and reimbursement support is designed to deliver exactly that.

Non-exclusive representation also gives Polarean flexibility. The company can layer additional partners or expand its internal team without being locked into a single channel.

Key numbers and facts at a glance

US coverage via Ascend Imaging	19 states (up from 4)
Agreement type	Non-exclusive independent manufacturer’s representative
Product focus	Xenon MRI platform, including XENOVIEW
Regulatory status	XENOVIEW is FDA-approved in the United States
Indication (per label)	Evaluation of lung ventilation in adults and paediatric patients aged 6 years and older
Limitations of use	Not evaluated for lung perfusion imaging
Contraindications	None

Clinical and safety notes investors should keep in mind

Two operational points from the label matter for clinical workflow:

• Supplemental oxygen can degrade image quality if given simultaneously. The label instructs withholding oxygen for two breaths before XENOVIEW inhalation, then resuming immediately after the imaging breath hold.
• Transient hypoxia risk means monitoring oxygen saturation and symptoms during the procedure, treating as needed.

Adverse reactions reported include oropharyngeal pain, headache and dizziness in adults. In published literature for ages 6 to 18, transient oxygen desaturation, heart rate elevation, numbness, tingling, dizziness and euphoria have been reported. The RNS notes XENOVIEW is not approved for use in paediatric patients less than 12 years of age.

What success looks like from here

Execution will be judged on the following over the coming quarters:

• New site wins and installations in the expanded 19-state footprint.
• Evidence of accelerating sales cycles, aided by Ascend’s access to decision-makers.
• Updates on reimbursement utilisation by hospitals, given it is cited as a driver of adoption.
• Complementary expansion of Polarean’s internal commercial team and any additional channel partners.

Risks and balanced view

Coverage is not the same as conversion. More states increase the opportunity set but do not guarantee orders. The non-exclusive structure cuts both ways: it provides flexibility for Polarean and implies Ascend can represent other technologies, so focus and incentives matter.

Crucially, the RNS does not provide financial targets, commission terms, or a timeline to revenue impact. Investors should treat this as a necessary step to scale distribution, with the payoff to be proven in forthcoming commercial updates.

My take for retail investors

This is a sensible and positive move for a commercial-stage imaging company. The addressable market broadens from a handful of states to a sizeable slice of the US, with a specialist partner positioned to unlock hospital conversations. The CEO’s language suggests the relationship is already working, which is reassuring.

That said, share prices respond to orders, not footprints. The next catalysts need to be concrete: named institutions, purchase orders, and installed system growth. Until then, treat this as a strategically useful, credibility-enhancing step that lays groundwork for future revenue rather than an immediate top-line trigger.